PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
ARQT vs. SMMT
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between ARQT and SMMT is 0.22, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

ARQT vs. SMMT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Arcutis Biotherapeutics, Inc. (ARQT) and Summit Therapeutics Inc. (SMMT). The values are adjusted to include any dividend payments, if applicable.

0.00%500.00%1,000.00%1,500.00%2,000.00%JulyAugustSeptemberOctoberNovemberDecember
-31.24%
1,067.97%
ARQT
SMMT

Key characteristics

Sharpe Ratio

ARQT:

5.57

SMMT:

2.14

Sortino Ratio

ARQT:

4.55

SMMT:

5.44

Omega Ratio

ARQT:

1.54

SMMT:

1.72

Calmar Ratio

ARQT:

5.15

SMMT:

7.48

Martin Ratio

ARQT:

22.35

SMMT:

25.41

Ulcer Index

ARQT:

21.42%

SMMT:

25.07%

Daily Std Dev

ARQT:

85.91%

SMMT:

298.18%

Max Drawdown

ARQT:

-95.02%

SMMT:

-95.75%

Current Drawdown

ARQT:

-59.46%

SMMT:

-44.03%

Fundamentals

Market Cap

ARQT:

$1.74B

SMMT:

$13.78B

EPS

ARQT:

-$1.67

SMMT:

-$0.23

Total Revenue (TTM)

ARQT:

$138.71M

SMMT:

-$235.00K

Gross Profit (TTM)

ARQT:

$124.04M

SMMT:

-$907.00K

EBITDA (TTM)

ARQT:

-$167.33M

SMMT:

-$184.77M

Returns By Period

In the year-to-date period, ARQT achieves a 364.09% return, which is significantly lower than SMMT's 584.67% return.


ARQT

YTD

364.09%

1M

47.25%

6M

76.56%

1Y

476.54%

5Y*

N/A

10Y*

N/A

SMMT

YTD

584.67%

1M

-2.99%

6M

125.35%

1Y

654.01%

5Y*

65.57%

10Y*

N/A

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

ARQT vs. SMMT - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Arcutis Biotherapeutics, Inc. (ARQT) and Summit Therapeutics Inc. (SMMT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for ARQT, currently valued at 5.57, compared to the broader market-4.00-2.000.002.005.572.14
The chart of Sortino ratio for ARQT, currently valued at 4.55, compared to the broader market-4.00-2.000.002.004.004.555.44
The chart of Omega ratio for ARQT, currently valued at 1.54, compared to the broader market0.501.001.502.001.541.72
The chart of Calmar ratio for ARQT, currently valued at 5.15, compared to the broader market0.002.004.006.005.158.08
The chart of Martin ratio for ARQT, currently valued at 22.35, compared to the broader market-5.000.005.0010.0015.0020.0025.0022.3525.41
ARQT
SMMT

The current ARQT Sharpe Ratio is 5.57, which is higher than the SMMT Sharpe Ratio of 2.14. The chart below compares the historical Sharpe Ratios of ARQT and SMMT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.002.004.006.00JulyAugustSeptemberOctoberNovemberDecember
5.57
2.14
ARQT
SMMT

Dividends

ARQT vs. SMMT - Dividend Comparison

Neither ARQT nor SMMT has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

ARQT vs. SMMT - Drawdown Comparison

The maximum ARQT drawdown since its inception was -95.02%, roughly equal to the maximum SMMT drawdown of -95.75%. Use the drawdown chart below to compare losses from any high point for ARQT and SMMT. For additional features, visit the drawdowns tool.


-80.00%-60.00%-40.00%-20.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-59.46%
-44.03%
ARQT
SMMT

Volatility

ARQT vs. SMMT - Volatility Comparison

Arcutis Biotherapeutics, Inc. (ARQT) has a higher volatility of 23.51% compared to Summit Therapeutics Inc. (SMMT) at 17.79%. This indicates that ARQT's price experiences larger fluctuations and is considered to be riskier than SMMT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


20.00%40.00%60.00%80.00%100.00%120.00%140.00%JulyAugustSeptemberOctoberNovemberDecember
23.51%
17.79%
ARQT
SMMT

Financials

ARQT vs. SMMT - Financials Comparison

This section allows you to compare key financial metrics between Arcutis Biotherapeutics, Inc. and Summit Therapeutics Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab